Member News
Quark Venture Inc. and GF Securities Participate in Keros Therapeutics’ $23 million Series B Financing for Development of Therapies to Treat Debilitating Neuromuscular Diseases
Vancouver, BC – Quark Venture Inc. (Quark) and GF Securities are pleased to announce their investment in Keros Therapeutics, a company dedicated to the discovery and development of novel therapeutics… Read More